Irina Ciubotaru is an Endocrinology/Metabolic physician. OpenAlex indexes 9 publications with 372 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 E Ryan Rd
Oak Creek, WI 531544563
Telephone
414-570-3590Provider last certified this registry record 19 Feb 2026.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year20251 payment
- Insulet CorporationProgram year202410 payments
- Novo Nordisk IncProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
75.4%Insulin Analog27.3%Lantus Solostar25%Humalog Kwikpen U-10010%Novolog Flexpen9%Tresiba Flextouch U-2008%Insulin Lispro Kwikpen U-1008%Humalog7%Tresiba Flextouch U-1004%Humalog Kwikpen U-2004%Basaglar Kwikpen U-1004%Novolog3%Insulin Aspart Flexpen3%Semglee (Yfgn) Pen3%Insulin Lispro2%Insulin Glargine-Yfgn2%Levemir Flexpen2%Soliqua 100-332%Lantus1%Fiasp Flextouch1%Toujeo Solostar1%Toujeo Max Solostar1%Lyumjev Kwikpen U-1001%Part D<11 patientsGLP-1 receptor agonist17.1%Ozempic67%Trulicity24%Mounjaro8%Part D≥105 patients+ 7 more classes in this area
Hormonal (systemic)
19.5%l-Thyroxine16.2%Levothyroxine Sodium93%Synthroid6%Levoxyl2%Part D<11 patientsThyroid Hormone Synthesis Inhibitor2.6%Methimazole100%Part D≥34 patients+ 1 more class in this area
Cardiovascular
4.5%Statin3.1%Atorvastatin Calcium76%Pravastatin Sodium13%Rosuvastatin Calcium12%Part D<11 patientsPeroxisome Proliferator-activated Receptor alpha Agonist0.4%Fenofibrate100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Siguranța pacienților şi procedurile invazive
Culegere de rezumate științifice ale studenților, rezidenților și tinerilor cercetători
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”